188 related articles for article (PubMed ID: 18185958)
41. An overview of erdosteine antioxidant activity in experimental research.
Moretti M; Marchioni CF
Pharmacol Res; 2007 Apr; 55(4):249-54. PubMed ID: 17267240
[TBL] [Abstract][Full Text] [Related]
42. Mucoactive agents for airway mucus hypersecretory diseases.
Rogers DF
Respir Care; 2007 Sep; 52(9):1176-93; discussion 1193-7. PubMed ID: 17716385
[TBL] [Abstract][Full Text] [Related]
43. [Multicenter, controlled, double-blind study of the efficacy and tolerance of Vectrine (erdostein) versus placebo in the treatment of stabilized chronic bronchitis with hypersecretion].
Aubier M; Berdah L
Rev Mal Respir; 1999 Sep; 16(4):521-8. PubMed ID: 10549062
[TBL] [Abstract][Full Text] [Related]
44. Pemphigus herpetiformis-type drug reaction caused by erdosteine containing mucolytic in a child.
Akoglu G; Yavuz SO
Cutan Ocul Toxicol; 2017 Sep; 36(3):302-304. PubMed ID: 27881029
[TBL] [Abstract][Full Text] [Related]
45. Erdosteine protects HEI-OC1 auditory cells from cisplatin toxicity through suppression of inflammatory cytokines and induction of Nrf2 target proteins.
Kim SJ; Park C; Lee JN; Lim H; Hong GY; Moon SK; Lim DJ; Choe SK; Park R
Toxicol Appl Pharmacol; 2015 Oct; 288(2):192-202. PubMed ID: 26193055
[TBL] [Abstract][Full Text] [Related]
46. Effect of a single 1200 Mg dose of Mucinex® on mucociliary and cough clearance during an acute respiratory tract infection.
Bennett WD; Kala A; Duckworth H; Zeman KL; Wu J; Henderson A; Yopp M; Rubin BK
Respir Med; 2015 Nov; 109(11):1476-83. PubMed ID: 26462765
[TBL] [Abstract][Full Text] [Related]
47. Prevention of pulmonary complications of pneumoperitoneum in rats.
Karapolat S; Gezer S; Yildirim U; Dumlu T; Karapolat B; Ozaydin I; Yasar M; Iskender A; Kandis H; Saritas A
J Cardiothorac Surg; 2011 Feb; 6():14. PubMed ID: 21303502
[TBL] [Abstract][Full Text] [Related]
48. [ Erdosteine (Mucodox), oral administration].
J Pharm Belg; 2011 Jun; (2):55-6. PubMed ID: 21823444
[No Abstract] [Full Text] [Related]
49. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis.
Cazzola M; Rogliani P; Calzetta L; Hanania NA; Matera MG
COPD; 2017 Oct; 14(5):552-563. PubMed ID: 28753070
[TBL] [Abstract][Full Text] [Related]
50. Appropriate use of antitussives and protussives. A practical review.
Irwin RS; Curley FJ; Bennett FM
Drugs; 1993 Jul; 46(1):80-91. PubMed ID: 7691510
[TBL] [Abstract][Full Text] [Related]
51. Effect of erdosteine and its metabolites on tracheobronchial mucus production and transport.
Scuri R; Giannetti P; Paesano A
Drugs Exp Clin Res; 1988; 14(11):693-8. PubMed ID: 3246214
[TBL] [Abstract][Full Text] [Related]
52. [Effects of erdosteine on inflammation and fibrosis in rats with pulmonary fibrosis induced by bleomycin].
Karapolat S
Tuberk Toraks; 2009; 57(2):244-5; author reply 245-6. PubMed ID: 19714520
[No Abstract] [Full Text] [Related]
53. Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease.
Moretti M
Expert Rev Respir Med; 2007 Dec; 1(3):307-16. PubMed ID: 20477170
[TBL] [Abstract][Full Text] [Related]
54. Tissue-Protective Effect of Erdosteine on Multiple-Organ Injuries Induced by Fine Particulate Matter.
Cao L; Ping F; Zhang F; Gao H; Li P; Ning X; Cui G; Ma Z; Jiang X; Li S; Han S
Med Sci Monit; 2021 Dec; 27():e930909. PubMed ID: 34873140
[TBL] [Abstract][Full Text] [Related]
55. The effects of erdosteine, N-acetylcysteine, and vitamin E on nicotine-induced apoptosis of pulmonary cells.
Demiralay R; Gürsan N; Erdem H
Toxicology; 2006 Feb; 219(1-3):197-207. PubMed ID: 16377052
[TBL] [Abstract][Full Text] [Related]
56. Erdosteine and ebselen as useful agents in intestinal ischemia/reperfusion injury.
Tunc T; Uysal B; Atabek C; Kesik V; Caliskan B; Oztas E; Ersoz N; Oter S; Guven A
J Surg Res; 2009 Aug; 155(2):210-6. PubMed ID: 19505699
[TBL] [Abstract][Full Text] [Related]
57. Antioxidant effect of erdosteine and lipoic acid in ovarian ischemia-reperfusion injury.
Dokuyucu R; Karateke A; Gokce H; Kurt RK; Ozcan O; Ozturk S; Tas ZA; Karateke F; Duru M
Eur J Obstet Gynecol Reprod Biol; 2014 Dec; 183():23-7. PubMed ID: 25461347
[TBL] [Abstract][Full Text] [Related]
58. Erdosteine ameliorates lung injury induced by transient aortic occlusion in rats.
Kurtoglu T; Sacar M; Inan BK; Duver MH; Guler A; Ucak A; Us MH; Yilmaz AT
Cardiovasc J Afr; 2007; 18(6):367-70. PubMed ID: 18092111
[TBL] [Abstract][Full Text] [Related]
59. Erdosteine in children and adults with bronchiectasis (BETTER trial): study protocol for a multicentre, double-blind, randomised controlled trial.
Chang AB; Yerkovich ST; Baines KJ; Burr L; Champion A; Chatfield MD; Eg KP; Goyal V; Marsh RL; McCallum GB; McElrea M; McPhail S; Morgan LC; Morris PS; Nathan AM; O'Farrell H; Sanchez MO; Parsons M; Schultz A; Torzillo PJ; West NP; Versteegh L; Marchant JM; Grimwood K
BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38719503
[TBL] [Abstract][Full Text] [Related]
60. Effects of erdosteine on cyclosporin-A-induced nephrotoxicity.
Tutanc M; Arica V; Yılmaz N; Nacar A; Zararsiz I; Basarslan F; Tutanc OD; Nacar E
Hum Exp Toxicol; 2012 Jun; 31(6):565-73. PubMed ID: 21813577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]